Loading clinical trials...
Loading clinical trials...
An Open-Label Phase I Study of JAK Inhibitor Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Conditions
Interventions
Ruxolitinib
Abatacept
Locations
1
United States
Washington University School of Medicine
St Louis, Missouri, United States
Start Date
May 7, 2024
Primary Completion Date
September 8, 2027
Completion Date
November 27, 2027
Last Updated
April 22, 2026
NCT07124078
NCT00106925
NCT06705062
NCT01804686
NCT07356245
NCT04745221
Lead Sponsor
Washington University School of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions